Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers

Medical Science Monitor

Volumn 19, Issue 1, 2013, Pages 875-882

  Celik, Betül ^a   Yalcin, Arzu Didem ^b,c   Bisgin, Atil ^d   Dimitrakopoulou Strauss, Antonia ^e   Kargi, Aysegül ^b   Strauss, Ludwig G ^e  

^a Antalya Education and Research Hospital ^*  (Turkey)

^b Antalya Education and Research Hospital   (Turkey)

^c ACADEMIA SINICA   (Taiwan)

^d LINKÖPING UNIVERSITY   (Sweden)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anti VEGF antibody (bevacizumab); CXCL8 (IL8); F 18 Deoxyglucose positron emission tomography (FDG PET CT); Metastatic colorectal cancer (MCRC); Proteomics study; Soluble TRAIL (sTRAIL); SUVmax: standardized uptake maximum values

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 8; IRINOTECAN; OXALIPLATIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FUNCTIONAL PROTEOMICS; HUMAN; MALE; METASTATIC COLORECTAL CANCER; POSITRON EMISSION TOMOGRAPHY; STANDARDIZED UPTAKE MAXIMUM VALUE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; COLONIC NEOPLASMS; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; INTERLEUKIN-8; POSITRON-EMISSION TOMOGRAPHY; PROTEOMICS; STATISTICS, NONPARAMETRIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84886286912     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889605     Document Type: Article

References (39)

1. Valentini V, Coco C, Gambacorta MA et al: Evidence and research perspectives for surgeons in the European Rectal Cancer Consensus Conference (EURECA-CC2). Acta Chir Iugosl, 2010; 57(3): 9-16
2. Weitz J, Koch M, Debus J et al: Colorectal cancer. Lancet, 2005, 365: 153-65
3. Jass JR, Whitehall VL, Young J et al: Emerging concepts in colorectal neoplasia. Gastroenterology, 2002; 123: 862-76
4. Steinbach G, Lynch PM, Phillips RK et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med, 2000; 342: 1946-52
5. Opferman JT, Korsmeyer SJ: Apoptosis in the development and maintenance of the immune system. Nat Immunol, 2003; 4(5): 410-15
6. Holland PM: Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL. Cancer Lett 2013, 332(2): 156-62
7. Wandinger KP, Lünemann JD, Wengert O et al: TNF related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet, 2003; 361(9374): 2036-43
8. Ding W, Cai T, Zhu H et al: Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo. Cancer Lett, 2010; 293: 158-66
9. Kargi A, Yalcin AD, Erin N et al: IL8 and Serum Soluble TRAIL Levels Following AntiVEGF Monoclonal Antibody Treatment in Patients With Metastatic Colon Cancer. Clin Lab, 2012; 58(5-6): 501-5. Erratum in: Clin Lab, 2012; 58(9-10): 1103-7
10. Varney ML, Singh S, Li A et al: Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett, 2011; 300(2): 180-88
11. Oladipo O, Conlon S, O'Grady A et al: The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer, 2011; 104(3): 480-87
12. Chen Y, Shi M, Yu GZ et al: Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol, 2012; 18(10): 1123-29
13. Dimberg J, Ström K, Löfgren S et al: DNA promoter methylation status and protein expression of interleukin-8 in human colorectal adenocarcinomas. Int J Colorectal Dis, 2012; 27(6): 709-14
14. Delbeke D, Vitola JV, Sandler MP et al: Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med, 1997; 38: 1120-96
15. Strauss LG, Conti PS: The applications of PET in clinical oncology. J Nucl Med, 1991; 32: 623-48
16. Schiepers C, Penninckx F, De Vadder N et al: Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol, 1995; 21: 517-22
17. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med, 2002; 8(4 Suppl.): S62-67
18. Pedersen MW, Holm S, Lund EL et al: Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two smallcell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia, 2001; 3(1): 80-87
19. Strauss LG, Koczan D, Klippel S et al: Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med, 2008; 49: 1238-44
20. Bisgin A, Kargi A, Yalcin AD et al: Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. BMC Cancer, 2012; 12: 58
21. Granci V, Bibeau F, Kramar A et al: Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer, 2008; 44: 2312-18
22. Ning Y, Manegold PC, Hong YK et al: Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer, 2011; 128(9): 2038-49
23. Carmeliet P: Angiogenesis in health and disease. Nat Med, 2003; 9: 653-60
24. Gerger A, Labonte M, Lenz HJ: Molecular predictors of response to antiangiogenesis therapies. Cancer J, 2011; 17: 134-41
25. Jubb AM, Harris AL: Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol, 2010; 11: 1172-83
26. Hayes DF: Bevacizumab treatment for solid tumors: boon or bust? JAMA, 2011; 305: 506-8
27. Cunningham D, Atkin W, Lenz HJ et al: Colorectal cancer. Lancet, 2010; 375: 1030-47
28. Welch S, Spithoff K, Rumble RB, Maroun J: Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol, 2010; 21: 1152-62
29. Shi J, Zheng D, Liu Y et al: Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res, 2005; 65(5): 1687-92, Erratum in: Cancer Res, 2005; 65(9): 3966
30. Cantarella G, Risuglia N, Dell'eva R et al: TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer, 2006; 94(10): 1428-35
31. Perik PJ, Van der Graaf WT, De Vries EG et al: Circulating apoptotic proteins were increased in long-term disease-free breast cancer survivors. Acta Oncol, 2006; 45(2): 175-83
32. Ferrara N: Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev, 2010; 21: 21-26
33. Waugh DJ, Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res, 2008; 14: 6735-41
34. Cao Y, Zhong W, Sun Y: Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol, 2009; 19: 338-43
35. Schultheis AM, Lurje G, Rhodes KE et al: Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res, 2008; 14: 7554-63
36. Gabellini C, Trisciuoglio D, Desideri M et al: Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer, 2009; 45(14): 2618-27
37. Huebner RH, Park KC, Shepherd JE et al: A meta-analysis of the literature for whole-body FDG-PET detection of recurrent colorectal cancer. J Nucl Med, 2000; 41: 1177-89
38. Delbeke D, Vitola JV, Sandler MP et al: Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med, 1997; 38: 1120-96
39. Strauss LG, Koczan D, Klippel S et al: Impact of cell-proliferation-associated gene expression on 2-deoxy-2-(18)f]fluoro-D-glucose (FDG) kinetics as measured by dynamic positron emission tomography (dPET) in colorectal tumors. Mol Imaging Biol, 2011; 13(6): 1290-300